Fiona Marshall
@FionaHMarshall
Drug hunter, molecular pharmacologist, neuroscientist. President, Biomedical Research @Novartis. Views are my own.
I’m pleased to share that Novartis has entered a collaboration with @bioagelabs aimed at discovering novel targets for potential therapies for age-related diseases. We look forward to the groundbreaking discoveries that this collaboration could bring. ir.bioagelabs.com/news-releases/…

Thank you to @GoogleDeepMind and @royalsociety for inviting me to take part in the AI for Science Forum—and to fellow panelists @EricTopol, Alison Noble, and @pushmeet for the insightful discussion on the transformative potential and impact of #AI on scientific discovery.
How can AI revolutionize the scientific method to bring in a new age of discovery? @EricTopol chaired a fascinating discussion with our VP Science, @Pushmeet and leading biomedical researchers @AlisonNoble_OU (Vice President, Royal Society) and @FionaHMarshall (President of…
Pleased to share that Novartis has acquired Kate Therapeutics. This is an exciting deal that will add to our expertise and capabilities to help us advance novel gene therapies with transformative potential for people with inherited neuromuscular diseases. novartis.com/stories/addres…

I’m happy to share that we’ve entered into a strategic collaboration with @VyriadMN to discover and develop in vivo CAR-T cell therapies to expand the potential of CAR-Ts to benefit a broader range of patients. vyriad.com/newsevents/vyr…

Very happy to share that Novartis is collaborating with @Ratio_Tx to advance a next-generation RLT candidate, and bring forward additional therapeutic options for patients with difficult to treat cancer. ratiotx.com/2024/11/18/nov…
I’m excited to share that we've entered into a research collaboration and expanded software licensing agreement with Schrödinger, combining our research capabilities with Schrödinger’s computational chemistry tools to enhance our drug discovery efforts. fiercebiotech.com/biotech/novart…
Excited to share that the FDA has approved our medicine as a first-line treatment for adults with Ph+ CML in chronic phase – a testament to our researchers’ commitment to innovating new therapies to address unmet needs of cancer patients. novartis.com/news/media-rel…

I’m happy to share that Novartis and @MonteRosaTx have announced an exclusive global development and commercialization license agreement to advance molecular glue degraders. ir.monterosatx.com/news-releases/…

It was a pleasure to speak with C&EN about AlphaFold and the Nobel Prize-winning tech powering next-gen structure-based drug design—including our work with @demishassabis @IsomorphicLabs, using #AI to accelerate the drug discovery process cen.acs.org/people/nobel-p…
Congrats to our Global Health research team, who describe the discovery of a preclinical, GI-targeted oral molecule for the potential treatment of pediatric cryptosporidiosis in @NatureMicrobiol. nature.com/articles/s4156…

Delighted to see our @IsomorphicLabs collaborator @demishassabis, along with John Jumper and David Baker, awarded the Nobel Prize in Chemistry for computational approaches to protein prediction & design—brilliant work with the potential to transform drug discovery. Congrats, all!
We are thrilled to share the breaking news that our CEO and founder @demishassabis and @GoogleDeepMind colleague John Jumper have been awarded the 2024 Nobel Prize in Chemistry for their groundbreaking work creating AlphaFold alongside David Baker for computational protein…
I’m excited to share that Novartis and @generate_biomed will collaborate to apply generative #AI to the discovery of next-gen biologics -- another example of our commitment to leveraging promising AI tools to help accelerate #drugdiscovery and development businesswire.com/news/home/2024…

So glad I could be present to celebrate this milestone. @FMIscience is a research powerhouse. I have no doubt this amazing new facility will be the home of many transformativediscoveries in the coming years.
Exciting day at the Novartis campus as the new FMI building opens its doors! Distinguished guests, including politicians, media & Novartis leaders, gathered to celebrate the exceptional collaboration between the FMI, @Novartis_CH & @UniBasel. Read more at: fmi.ch/news-events/ar…
This exciting news from the FDA brings a new treatment option to the US for reduction of proteinuria in certain adults with IgA nephropathy. Congratulations to all who helped achieve this milestone, including the many patients and clinicians who participated in clinical trials.
Novartis announces FDA accelerated approval of first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (#IgAN). novartis.social/6019lYlrf #RareDisease #NovartisNews
I’m pleased to share that Novartis has entered into a collaboration agreement with Dren Bio to discover and advance novel antibody-based immune cell engagers for certain cancers. businesswire.com/news/home/2024…
I had a wonderful visit to our San Diego Biomedical Research hub where I met with many of our remarkable scientists, including contributors to this ingenious technology. Exciting to see the work spark valuable insights in the hunt for new heart disease drugs.…

This is an exciting opportunity to learn from brilliant mentors while applying your AI and #datascience skills in the field of drug discovery. Recent PhD graduates are encouraged to apply by July 29. linkedin.com/posts/novartis…
Excited to see this published in @ScienceMagazine—our team’s paper on the discovery of molecular glue degraders to induce fetal hemoglobin—a potential avenue toward creating an accessible oral therapy for #sicklecelldisease. Congrats to @PamelaTing, @jaybradner and all involved…

It was a pleasure to join leaders of our LGBTQI community and so many more Cambridge colleagues for this year’s Pride flag-raising event. Thank you to all who attended to celebrate equity, inclusion, dignity, and visibility to kick off #PrideMonth this year.
The fight against malaria has been marked by numerous highs and lows, but our commitment to eliminate the disease remains unwavering. We need to act now to make malaria a problem of the past. #WHA77 #EndMalaria #Malaria @HarvardChanSPH @endmalaria